{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:37:26Z","timestamp":1794937046567,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.parkreldis.2021.02.008","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:16:05Z","timestamp":1613607365000},"page":"11-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study"],"prefix":"10.1016","volume":"85","author":[{"given":"Rong","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Locascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8577-2090","authenticated-orcid":false,"given":"Anna E.","family":"Goodheart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moqing","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen N.","family":"Gomperts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.parkreldis.2021.02.008_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"13","key":"10.1016\/j.parkreldis.2021.02.008_bib2","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms","volume":"92","author":"Marques","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.parkreldis.2021.02.008_bib3","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","article-title":"NfL as a biomarker for neurodegeneration and survival in Parkinson disease","volume":"95","author":"Backstrom","year":"2020","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.parkreldis.2021.02.008_bib4","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: a biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.008_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","article-title":"Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease","volume":"15","author":"Ng","year":"2020","journal-title":"Mol. Neurodegener."},{"issue":"24","key":"10.1016\/j.parkreldis.2021.02.008_bib6","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1212\/WNL.0000000000002768","article-title":"Postural instability and gait are associated with severity and prognosis of Parkinson disease","volume":"86","author":"van der Heeden","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.parkreldis.2021.02.008_bib7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/mds.20897","article-title":"Changes in motor subtype and risk for incident dementia in Parkinson's disease","volume":"21","author":"Alves","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2021.02.008_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.parkreldis.2016.04.027","article-title":"How stable are Parkinson's disease subtypes in de novo patients: analysis of the PPMI cohort?","volume":"28","author":"Simuni","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2021.02.008_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.parkreldis.2019.05.024","article-title":"Parkinson's disease motor subtype changes during 20 years of follow-up","volume":"76","author":"Eisinger","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2021.02.008_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00259-008-0989-5","article-title":"Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls","volume":"36","author":"Eshuis","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"4","key":"10.1016\/j.parkreldis.2021.02.008_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO;2-V","article-title":"Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2021.02.008_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.parkreldis.2020.04.009","article-title":"Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease","volume":"74","author":"Sampedro","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2021.02.008_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.25383","article-title":"How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale","volume":"28","author":"Stebbins","year":"2013","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2021.02.008_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mds.20513","article-title":"Clinical characteristics in early Parkinson's disease in a central California population-based study","volume":"20","author":"Kang","year":"2005","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.parkreldis.2021.02.008_bib15","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2021.02.008_bib16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.parkreldis.2021.02.008_bib17","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.28056","article-title":"CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories","volume":"35","author":"Lerche","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2021.02.008_bib18","series-title":"Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression","author":"Mollenhauer","year":"2020"},{"issue":"5","key":"10.1016\/j.parkreldis.2021.02.008_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jnnp.2005.081711","article-title":"Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies","volume":"77","author":"Burn","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.008_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00221-007-1024-y","article-title":"Assessment of postural instability in patients with Parkinson's disease","volume":"183","author":"Blaszczyk","year":"2007","journal-title":"Exp. Brain Res."},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.008_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","article-title":"Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"issue":"Suppl 7","key":"10.1016\/j.parkreldis.2021.02.008_bib22","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1002\/mds.10579","article-title":"Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?","volume":"18","author":"Pirker","year":"2003","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2021.02.008_bib23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1468-1331.2009.02898.x","article-title":"Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study","volume":"17","author":"Rossi","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.008_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.27183","article-title":"11) C-PE2I and (18) F-Dopa PET for assessing progression rate in Parkinson's: a longitudinal study","volume":"33","author":"Li","year":"2018","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.008_bib25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000330228","article-title":"An overview of longitudinal data analysis methods for neurological research","volume":"1","author":"Locascio","year":"2011","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.008_bib26","doi-asserted-by":"crossref","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","article-title":"Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease","volume":"8","author":"Lin","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.008_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson's progression Markers initiative cohort","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:21:21Z","timestamp":1761178881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802021000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":27,"alternative-id":["S1353802021000493"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.02.008","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}